neuroplastogenic therapeutics

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company specializing in neuroplastogenic therapeutics for anxiety, depression, and addiction disorders, has priced a $5 million public offering, a move that highlights both funding needs and potential shareholder dilution concerns. The offering consists of…